6-aminoisoquinoline compounds
View Patent ↗6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.
1. A compound according to Formula IV
wherein A is a substituted or unsubstituted chain containing from one to four member atoms selected from the group consisting of carbon, nitrogen, oxygen and sulphur, wherein the chain may be mono- or disubstituted with halogen, cyano, nitro, or C 1 -C 4 alkyl, or the substituted atoms may attach back to the main chain to form a ring;
wherein R 1 and R 2 are, independently, hydrogen, hydroxyl, halogen, or cyano; and
wherein R 3 is hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, amino, cyano, cycloalkyl, heterocycloalkyl, aryl, C 1 -C 4 alkyl aryl, heteroaryl, C 1 -C 4 alkyl heteroaryl, carbonyl, carbonylamino, thioalkyl, sulfonyl, sulfonylamino, acyl, or carboxyl.
2. The compound of claim 1 , wherein R 1 and R 2 are hydrogen.
3. The compound of claim 1 , wherein A is methylene or ethylene.
4. The compound of claim 1 , wherein A is —O—CH 2 — or —NH—CH 2 —.
5. The compound of claim 1 , wherein R 3 is alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, C 1 -C 4 alkyl aryl, heteroaryl, C 1 -C 4 alkyl heteroaryl, carbonyl, or carbonylamino.
6. The compound of claim 1 , wherein R 3 is aryl.
7. The compound of claim 6 , wherein R 3 is substituted with heteroaryl, acyl, carboxyl, carbonylamino, nitro, amino, cyano, halogen, alkoxy, or hydroxyl.
8. The compound of claim 6 , wherein R 3 is phenyl.
9. The compound of claim 1 , selected from the following:
10. A pharmaceutical composition comprising:
a) the compound according to claim 1 ; and
b) a pharmaceutically acceptable carrier.
11. The composition of claim 10 , wherein the carrier is selected from the group consisting of systemic and topical carriers.
12. The composition of claim 11 , wherein the composition comprises about 0.001% to 10% of the 6-aminoisoquinoline derivative and 90 to 99.999% of the systemic carrier.